Press
Releases

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 6,...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in the Company's Phase 1a single ascending dose ("SAD")...

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter 2022 financial results after market close on May 10,...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal...

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M...

Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose...

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written notice (the "Notice") from the Listing Qualifications...

Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1M Immediate termination of Loan Agreement and release of security interests over all of its...

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022....

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 15, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today reported its financial results for...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – October 15, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that it has closed on the...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 28, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that its subsidiary...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – August 16, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –August 9, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that, its subsidiary Prometic...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –July 9, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 23, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that, Kedrion S.p.A...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 4, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) announced today that the U.S. Food & Drug...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 4, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) announced the voting results from its Annual...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –May 28, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –May 21, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –May 17, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – May 17, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – March 24, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

Company focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – January 12, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – Dec 14, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – December 7, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 13, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...

PDUFA Target Action Date of June 5, 2021 for Ryplazim® (plasminogen) BLA Submission Ryplazim® (plasminogen) Abstracts Selected for Presentation at American Society of Hematology (ASH) in early...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 10, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...

PDUFA date extended by FDA from March 5, 2021 to June 5, 2021 Earnings call moved forward to Wednesday November 11th LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 8, 2020 – Liminal...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 6, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 5, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – October 30, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company,...

FDA assigns PDUFA target action date of March 5, 2021 LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 21, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 9, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...

Results from pivotal phase 2/3 study met co-primary endpoints for improvement in trough plasminogen activity levels and reduction in lesion size Pending approval, potential for Ryplazim®...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – September 1, 2020 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...

Acquisition of OXER1 R&D Program Joined the CoVIg-19 Plasma Alliance Voluntary Delisting from Toronto Stock Exchange Net loss from continuing operations for Q2 2020 reduced by approximately 80%...

nt at Canaccord 40th Annual Growth Conference Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference AUGUST 6, 2020 SHRINAL INAMDAR LAVAL, QC, and CAMBRIDGE, ENGLAND – August...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 22, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 17, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 2, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – June 30, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – June 30, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...

LAVAL, QC, and CAMBRIDGE, UK – June 11, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today...

LAVAL, QC, and CAMBRIDGE, UK – June 9, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today...

LAVAL, QC, and CAMBRIDGE, UK – May 28, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today...

LAVAL, QC, and CAMBRIDGE, UK – May 13, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company today...

Measures taken to safeguard workforce and continuity of operations Recent FDA update on continued efforts to facilitate development of treatments LAVAL, QC and CAMBRIDGE, UK – March 22, 2020 –...

LAVAL, QC and CAMBRIDGE, UK – March 20, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company...

Fibrosis and tissue repair Obesity and non-alcoholic fatty liver disease LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – February 12, 2020 – Liminal BioSciences Inc. (NASDAQ & TSX:LMNL)...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – February 6, 2020 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – January 13, 2020 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences” or the “Company” ), a clinical-stage...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – December 23, 2019 – Liminal BioSciences Inc. (NASDAQ & TSX:LMNL) ( “Liminal BioSciences” or the “Company”), is issuing this news release in...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 28, 2019 – Liminal BioSciences Inc. (NASDAQ & TSX:LMNL) ( “Liminal BioSciences” or the “Company” ), a clinical-stage...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 27, 2019 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 25, 2019 – Liminal BioSciences Inc. (NASDAQ & TSX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 18, 2019 - Liminal BioSciences Inc. (NASDAQ: LMNL, TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 18, 2019 – Liminal BioSciences Inc. (NASDAQ: LMNL, TSX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage biotechnology...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 18, 2019 – Liminal BioSciences Inc. (NASDAQ: LMNL, TSX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage biotechnology...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 14, 2019 – Liminal BioSciences Inc. (TSX: LMNL, NASDAQ: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 15, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 13, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: LMNL) (“Liminal BioSciences" or the "Company"), a clinical-stage...

New preclinical data suggests PBI-4547 displays pleiotropic activities and has been shown to reduce non-alcoholic steatohepatitis (NASH), diabetes and fibrosis in different rodent models. LAVAL,...

Name change to Liminal BioSciences Inc. Divestment of UK bioseparations subsidiary to KKR for up to GBP 45 million in gross proceeds, of which GBP 32 million to be received upon closing Net loss...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 11, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 11, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences” or the “Company”), a biopharmaceutical...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – November 4, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences” or the “Company”), a clinical-stage...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 29, 2019 –Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences” or the “Company”), a clinical-stage small...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 25, 2019 – Liminal BioSciences Inc. (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage small molecules company...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 24, 2019 – Liminal BioSciences Inc. (TSX: LMNL) (“Liminal BioSciences”), a biopharmaceutical company focused on developing novel...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 18, 2019 – Liminal BioSciences Inc. (TSX: LMNL, OTCQX: PFSCF) (“Liminal BioSciences" or the "Company"), a clinical-stage small molecules...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – October 3rd, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Company"), a biopharmaceutical company focused on...

Novel, orally active immuno-metabolic agent Potential therapy for NAFLD/NASH, metabolic syndrome and other liver diseases Fully owned and proprietary to Prometic LAVAL, CANADA, ROCKVILLE, USA and...

LAVAL, CANADA, ROCKVILLE, USA and CAMBRIDGE, UK – September 4, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel...

LAVAL, QUEBEC, CANADA, ROCKVILLE, MD, USA and CAMBRIDGE, UK – September 3, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Company"), a biopharmaceutical...

C$229 (US 173) million of outstanding debt converted into Common Shares C$114 (US$87) million in gross proceeds raised in concurrent financings Internal promotions within the management team for...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – August 8th, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCD) (Prometic), wishes to correct an error in its press release entitled...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – August 7th, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel...

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK – August 5, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCD) (Prometic), a biopharmaceutical company focused on developing novel...

LAVAL, CANADA, ROCKVILLE, USA and CAMBRIDGE, UK – July 2, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Corporation") is pleased to announce that the...

LAVAL, CANADA, ROCKVILLE, USA and CAMBRIDGE, UK – June 19, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced the voting results...

Full allocation of exercised rights Gross proceeds raised of C$38 million (or US$ 28.4 million) LAVAL, CANADA, ROCKVILLE, USA and CAMBRIDGE, UK – June 17, 2019 – Prometic Life Sciences Inc. (TSX:

LAVAL, QC, CANADA, ROCKVILLE, MD, USA and CAMBRIDGE, UK – June 14, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing...

LAVAL, QUEBEC, CANADA; ROCKVILLE, MD, USA and CAMBRIDGE, UK – May 30, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing...

LAVAL, QUEBEC, CANADA and CAMBRIDGE, UK – May 22, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of three scientific posters on the...

LAVAL, QUEBEC, CANADA – May 15, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) ("Prometic" or the "Corporation") is pleased to confirm the terms of its previously announced equity...

Completion of recapitalization transactions and $75 million in gross proceeds secured from equity offering New CEO, Board appointees and management structure to strengthen Corporation’s...

Laval, Québec, Canada, Cambridge, UK, – May 8, 2019 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“Prometic” or “Corporation”) is pleased to announce today a new management...

LAVAL, QC, April 23, 2019 Stefan Clulow appointed as Chair of the Board Kenneth Galbraith appointed as Chief Executive Officer LAVAL, QC, April 23, 2019 /CNW Telbec/ - Prometic Life Sciences Inc....

LAVAL, QUEBEC, CANADA – April 15, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today its intention to enter into a series of...

Key Events for 2018:Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 Significant increase in bioseparation 2018 revenues to $22.7 million, a 35% increase over 2017 Net...

LAVAL, QUEBEC, CANADA – March 26, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today that it will report its financial...

LAVAL, QUEBEC, CANADA – March 25, 2019 – Prometic Life Sciences Inc. (TSX:PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today that it has secured an additional USD $5...

LAVAL, QUEBEC, CANADA – February 25, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) announced today that it has secured an additional USD...

LAVAL, QUEBEC, CANADA – February 14, 2019 – Prometic Life Sciences Inc. (TSX: PLI, OTCQX: PFSCF) (“Prometic” or the “Corporation”) today announced that it has engaged Lazard to review...